Role of pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics

Journal of Medical Microbiology

Volumn 63, Issue PART 4, 2014, Pages 544-555

  Kumari, Hansi ^a   Balasubramanian, Deepak ^a,b,c   Zincke, Diansy ^a,b   Mathee, Kalai ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE AMPR; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; DORIPENEM; ENZYME; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL VIRULENCE; BROTH DILUTION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG EXPOSURE; EPSILOMETER TEST; GENE EXPRESSION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; SUBINHIBITORY CONCENTRATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; PSEUDOMONAS AERUGINOSA; QUINOLONES; TRANSCRIPTIONAL ACTIVATION;

EID: 84897836308     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.070185-0     Document Type: Article

References (74)

1. Alvarez-Ortega, C., Wiegand, I., Olivares, J., Hancock, R. E. & Martínez, J. L. (2011). The intrinsic resistome of Pseudomonas aeruginosa to β-lactams. Virulence 2, 144-146.
2. Amsler, K., Santoro, C., Foleno, B., Bush, K. & Flamm, R. (2010). Comparison of broth microdilution, agardilution, and Etest for susceptibility testing of doripenem against Gram-negative and Grampositive pathogens. J Clin Microbiol 48, 3353-3357.
3. Andersson, D. I. & Hughes, D. (2011). Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev 35, 901-911.
4. Angus, B. L., Carey, A. M., Caron, D. A., Kropinski, A. M. & Hancock, R. E. (1982). Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrob Agents Chemother 21, 299-309.
5. Arendrup, M., Lundgren, B., Jensen, I. M., Hansen, B. S. & Frimodt-Møller, N. (2001). Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J Antimicrob Chemother 47, 521-526.
6. Bagge, N., Schuster, M., Hentzer, M., Ciofu, O., Givskov, M., Greenberg, E. P. & Høiby, N. (2004). Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother 48, 1175-1187.
7. Balasubramanian, D., Kong, K. F., Jayawardena, S. R., Leal, S. M., Sautter, R. T. & Mathee, K. (2011). Co-regulation of β-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa. J Med Microbiol 60, 147-156.
8. Balasubramanian, D., Schneper, L., Merighi, M., Smith, R., Narasimhan, G., Lory, S. & Mathee, K. (2012). The regulatory repertoire of Pseudomonas aeruginosa AmpC β-lactamase regulator AmpR includes virulence genes. PLoS ONE 7, e34067.
9. Balasubramanian, D., Kumari, H., Jaric, M., Fernandez, M., Turner, K. H., Dove, S. L., Narasimhan, G., Lory, S. & Mathee, K. (2013a). Deep sequencing analyses expands the Pseudomonas aeruginosa AmpR regulon to include small RNA-mediated regulation of iron acquisition, heat shock and oxidative stress response. Nucleic Acids Res.
10. Balasubramanian, D., Schneper, L., Kumari, H. & Mathee, K. (2013b). A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res 41, 1-20.
11. Baquero, F. & Negri, M. C. (1997). Selective compartments for resistant microorganisms in antibiotic gradients. BioEssays 19, 731-736.
12. Baquero, F., Martínez, J. L. & Cantón, R. (2008). Antibiotics and antibiotic resistance in water environments. Curr Opin Biotechnol 19, 260-265.
13. Barbier, F. & Wolff, M. (2010). [Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end?]. Med Sci (Paris) 26, 960-968 (in French).
14. Bonnin, R. A., Poirel, L., Nordmann, P., Eikmeyer, F. G., Wibberg, D., Pühler, A. & Schlüter, A. (2013). Complete sequence of broad-hostrange plasmid pNOR-2000 harbouring the metallo-β-lactamase gene blaVIM-2 from Pseudomonas aeruginosa. J Antimicrob Chemother 68, 1060-1065.
15. Boyd, N. & Nailor, M. D. (2011). Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 31, 1073-1084.
16. Bradford, P. A. (2001). Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14, 933-951.
17. Cabot, G., Ocampo-Sosa, A. A., Domínguez, M. A., Gago, J. F., Juan, C., Tubau, F., Rodríguez, C., Moyà, B., Peña, C. & other authors (2012). Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 56, 6349-6357.
18. Carmeli, Y., Troillet, N., Eliopoulos, G. M. & Samore, M. H. (1999). Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43, 1379-1382.
19. Castillo-Vera, J., Ribas-Aparicio, R. M., Nicolau, C. J., Oliver, A., Osorio-Carranza, L. & Aparicio-Ozores, G. (2012). Unusual diversity of acquired β-lactamases in multidrug-resistant Pseudomonas aeruginosa isolates in a Mexican hospital. Microb Drug Resist 18, 471-478.
20. CLSI (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard M7-A7, 7th edn. Wayne, PA: Clinical and Laboratory Standards Institute.
21. Curcio, D. (2013). Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge? Curr Clin Pharmacol 8, 1-12.
22. Cystic Fibrosis Foundation (2011). Patient Registry Annual Data Report. Bethesda: Maryland Cystic Fibrosis Foundation.
23. Davies, J., Spiegelman, G. B. & Yim, G. (2006). The world of subinhibitory antibiotic concentrations. Curr OpinMicrobiol 9, 445-453.
24. Fernández, L., Breidenstein, E. B. & Hancock, R. E. (2011). Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat 14, 1-21.
25. Giamarellou, H. & Kanellakopoulou, K. (2008). Current therapies for Pseudomonas aeruginosa. Crit Care Clin 24, 261-278, viii.
26. Girlich, D., Naas, T. & Nordmann, P. (2004). Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 48, 2043-2048.
27. Gooderham, W. J. & Hancock, R. E. (2009). Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 33, 279-294.
28. Gupta, V. (2008). Metallo b lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs 17, 131-143.
29. Hanson, N. D. & Sanders, C. C. (1999). Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr Pharm Des 5, 881-894.
30. Hennessey, T. D. (1967). Inducible β-lactamase in Enterobacter. J Gen Microbiol 49, 277-285.
31. Jacoby, G. A. (2009). AmpC β-lactamases. Clin Microbiol Rev 22, 161-182.
32. Johnson, S. J., Ernst, E. J. & Moores, K. G. (2011). Is double coverage of Gram-negative organisms necessary? Am J Health Syst Pharm 68, 119-124.
33. Kerr, K. G. & Snelling, A. M. (2009). Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 73, 338-344.
34. Köhler, T., Michéa-Hamzehpour, M., Henze, U., Gotoh, N., Curty, L. K. & Pechère, J.-C. (1997). Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 23, 345-354.
35. Köhler, T., Epp, S. F., Curty, L. K. & Pechère, J. C. (1999). Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 181, 6300-6305.
36. Kong, K. F., Jayawardena, S. R., Del Puerto, A., Wiehlmann, L., Laabs, U., Tümmler, B. & Mathee, K. (2005a). Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase. Gene 358, 82-92.
37. Kong, K. F., Jayawardena, S. R., Indulkar, S. D., Del Puerto, A., Koh, C. L., Høiby, N. & Mathee, K. (2005b). Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB β-lactamases, proteases, quorum sensing, and other virulence factors. Antimicrob Agents Chemother 49, 4567-4575.
38. Li, X. Z., Nikaido, H. & Poole, K. (1995). Role of mexA-mexβ-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 39, 1948-1953.
39. Lindberg, F. & Normark, S. (1986). Contribution of chromosomal blactamases to β-lactam resistance in enterobacteria. Rev Infect Dis 8 (Suppl. 3), S292-S304.
40. Lindquist, S., Lindberg, F. & Normark, S. (1989). Binding of the Citrobacter freundii AmpR regulator to a single DNA site provides both autoregulation and activation of the inducible ampC blactamase gene. J Bacteriol 171, 3746-3753.
41. Lister, P. D., Wolter, D. J. & Hanson, N. D. (2009). Antibacterialresistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22, 582-610.
42. Livermore, D. M. (1987). Clinical significance of β-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 6, 439-445.
43. Livermore, D. M. (2002). Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34, 634-640.
44. Livermore, D. M. & Yang, Y. J. (1987). β-Lactamase lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis 155, 775-782.
45. Lodge, J. M., Minchin, S. D., Piddock, L. J. & Busby, S. J. (1990). Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC blactamase. Biochem J 272, 627-631.
46. Lodge, J., Busby, S. & Piddock, L. (1993). Investigation of the Pseudomonas aeruginosa ampR gene and its role at the chromosomal ampC β-lactamase promoter. FEMS Microbiol Lett 111, 315-320.
47. Maseda, H., Saito, K., Nakajima, A. & Nakae, T. (2000). Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol Lett 192, 107-112.
48. Masuda, N., Gotoh, N., Ohya, S. & Nishino, T. (1996). Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 40, 909-913.
49. Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H. & Nishino, T. (2000). Substrate specificities of MexAβ-OprM, MexCDOprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44, 3322-3327.
50. McGowan, J. E., Jr (2006). Resistance in nonfermenting Gramnegative bacteria: multidrug resistance to the maximum. Am J Med 119 (Suppl. 1), S29-S36, discussion S62-S70.
51. Morita, Y., Tomida, J. & Kawamura, Y. (2012). MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol 3, 408.
52. Nikaido, H. (2003). Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67, 593-656.
53. Normark, S., Lindquist, S. & Lindberg, F. (1986). Chromosomal β-lactam resistance in enterobacteria. Scand J Infect Dis Suppl 49, 38-45.
54. Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52, 1.
55. Page, M. G. & Heim, J. (2009). Prospects for the next anti- Pseudomonas drug. Curr Opin Pharmacol 9, 558-565.
56. Pankuch, G. A., Lin, G., Hoellman, D. B., Good, C. E., Jacobs, M. R. & Appelbaum, P. C. (2006). Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies. Antimicrob Agents Chemother 50, 1727-1730.
57. Paul, M., Benuri-Silbiger, I., Soares-Weiser, K. & Leibovici, L. (2004). B Lactam monotherapy versus b lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328, 668.
58. Paul, M., Silbiger, I., Grozinsky, S., Soares-Weiser, K. & Leibovici, L. (2006). B Lactam antibiotic monotherapy versus b lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1, CD003344.
59. Pendleton, J. N., Gorman, S. P. & Gilmore, B. F. (2013). Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11, 297-308.
60. Poirel, L., Bonnin, R. A. & Nordmann, P. (2012). Genetic support and diversity of acquired extended-spectrum β-lactamases in Gramnegative rods. Infect Genet Evol 12, 883-893.
61. Poole, K., Gotoh, N., Tsujimoto, H., Zhao, Q., Wada, A., Yamasaki, T., Neshat, S., Yamagishi, J., Li, X. Z. & Nishino, T. (1996a). Overexpression of the mexC-mexD-oprJ efflux operon in nfxβ-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21, 713-725.
62. Poole, K., Tetro, K., Zhao, Q., Neshat, S., Heinrichs, D. E. & Bianco, N. (1996b). Expression of the multidrug resistance operon mexAmexβ- oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother 40, 2021-2028.
63. Rice, L. B. (2010). Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 31 (Suppl 1), S7-S10.
64. Rietsch, A., Vallet-Gely, I., Dove, S. L. & Mekalanos, J. J. (2005). ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 102, 8006-8011.
65. Sopirala, M. M., Mangino, J. E., Gebreyes, W. A., Biller, B., Bannerman, T., Balada-Llasat, J. M. & Pancholi, P. (2010). Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54, 4678-4683.
66. Stebbing, A. R. (1982). Hormesis -the stimulation of growth by low levels of inhibitors. Sci Total Environ 22, 213-234.
67. Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., Brinkman, F. S., Hufnagle, W. O., Kowalik, D. J. & other authors (2000). Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959-964.
68. Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. (2012). Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25, 450-470.
69. Vardakas, K. Z., Tansarli, G. S., Bliziotis, I. A. & Falagas, M. E. (2013). β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 41, 301-310.
70. Yeung, A. T., Bains, M. & Hancock, R. E. (2011). The sensor kinase CbrA is a global regulator thatmodulatesmetabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa. J Bacteriol 193, 918-931.
71. Yong, D., Toleman, M. A., Bell, J., Ritchie, B., Pratt, R., Ryley, H. & Walsh, T. R. (2012). Genetic and biochemical characterization of an acquired subgroup B3 metallo-β-lactamase gene, blaAIM-1, and its unique genetic context in Pseudomonas aeruginosa from Australia. Antimicrob Agents Chemother 56, 6154-6159.
72. Zavascki, A. P., Carvalhaes, C. G., Picão, R. C. & Gales, A. C. (2010). Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8, 71-93.
73. Zhao, W. H. & Hu, Z. Q. (2010). β-Lactamases identified in clinical isolates of Pseudomonas aeruginosa. Crit Rev Microbiol 36, 245-258.
74. Zhu, B., Zhang, P., Huang, Z., Yan, H. Q., Wu, A. H., Zhang, G. W. & Mao, Q. (2013). Study on drug resistance of Pseudomonas aeruginosa plasmid-mediated AmpC β-lactamase. Mol Med Rep 7, 664-668